Why the bone question is harder than the muscle question

Bone is the part of this subject where the honest answer is shortest. Substantial weight loss by any route reduces bone mineral density at the hip and femoral neck, has smaller and less consistent effects at the spine, and does so roughly in proportion to the weight lost. That has been observed in dietary weight loss, in bariatric surgery and, in the one secondary analysis to examine it in a trial combining a GLP-1 receptor agonist with exercise, in pharmacological weight loss as well. What none of this establishes is whether anybody breaks a bone as a result.

What the older-adult trials found

The closest analogue to rapid weight loss in an older, heavier population predates this drug class entirely. In a randomised trial of adults aged sixty-five and over with obesity, assigned to diet, exercise, both or a control condition for a year, the combination produced the largest improvement in physical function, and the exercise component attenuated the loss of lean mass and of bone mineral density that diet alone caused.¹ Diet alone improved function too — carrying less mass helps — but by less, and at a measurable skeletal cost.

That trial is the template for how the question should be asked in this class: randomise the co-intervention, measure function as a primary endpoint, measure bone, and follow for long enough for the skeleton to respond. Its population, older and heavier and losing weight quickly, resembles a large share of current incretin users far more closely than the young resistance-trained cohorts from which most consumer advice descends.

The Journal cites it frequently for that reason and notes the obvious limitation: the weight loss achieved was roughly a tenth of body mass over a year, which is half or less of what the current agents produce. Whether the protective effect of training holds at twice the rate of loss is not established.

What has been measured in bone

A secondary analysis of the Danish exercise-and-liraglutide trial is the only randomised evidence on bone in this class worth the name. It reported that exercise alone, or exercise combined with the agonist, preserved bone mineral density at clinically relevant sites, whereas the agonist alone was associated with reductions at the hip and spine relative to the exercise arms.² The effect sizes are small in absolute terms and the trial was not designed for this endpoint.

Around that sits a larger and older literature on dietary and surgical weight loss, which is consistent: substantial weight reduction lowers bone mineral density at load-bearing sites roughly in proportion to the mass lost, with the hip and femoral neck affected more than the lumbar spine, and with bariatric surgery producing the largest changes. Bone turnover markers rise early and remain elevated for months.

Two things are missing. There is no randomised bone endpoint in any trial of the current agents, at any dose, for any duration. And there is no fracture data at all — no trial in this class has been powered for fractures, none has reported them as a pre-specified outcome, and the observational literature is confounded by the fact that weight loss changes fall risk in both directions.

The soft-tissue artefact in bone densitometry

Densitometry infers bone mineral density from the differential attenuation of two X-ray energies, using the surrounding soft tissue as the baseline against which bone is distinguished. The algorithm assumes a soft-tissue composition, and that assumption is embedded in the calibration. When the thickness and fat fraction of the tissue overlying a measurement site change substantially, part of the apparent change in bone density is an artefact of the altered baseline.

The magnitude is contested. Phantom and cadaver work suggests errors of the order of one to three per cent for large changes in overlying fat, which is the same order as the real bone changes being reported over a year of rapid weight loss. In practice this means that a hip bone mineral density reduction of two per cent in a person who has lost a fifth of their body weight cannot be cleanly separated into a bone effect and a measurement effect, and the published analyses do not attempt it.

Quantitative computed tomography and high-resolution peripheral imaging are less vulnerable, measure geometry and microarchitecture rather than areal density, and have not been used in any trial in this class. The Journal regards that as the most easily closed gap in the whole body-composition literature.

Bioimpedance estimates total body water and infers the rest, so during rapid change it is estimating the quantity that is moving fastest. Its precision is good and its accuracy is a separate question, and the two are conflated constantly.

Is there a drug-specific skeletal effect?

Two hypotheses compete and both are underpowered. The first is that incretins are neutral for bone beyond making their users lighter, so any density change is the ordinary consequence of reduced mechanical loading. The second is that GLP-1 receptor signalling has direct skeletal effects — receptors have been reported on osteoblast lineage cells, and GLP-1 influences the entero-osseous axis and calcitonin secretion — which could be protective, harmful, or negligible.

The evidence cited for a protective effect is an early study of weight-loss maintenance in which liraglutide treatment was associated with preserved bone mineral density relative to a diet-alone comparison, interpreted at the time as a direct skeletal benefit.³ That finding sits awkwardly beside the later secondary analysis in which the agonist arm did worse than the exercise arms, and the two are not straightforwardly reconcilable: different agents at different doses, different comparators, different durations, small samples throughout.

The Journal reports the question as open, which is unsatisfying and accurate. What would settle it is a randomised bone endpoint with imaging that is not confounded by soft-tissue change, in a population whose weight loss is matched across arms. Nothing of that description is under way.

What the testing services can and cannot tell you here

A category confusion arrives in the Journal postbag with some regularity, and it is worth addressing directly. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse the contents of a vial. They report chromatographic purity, identity by mass, sometimes peptide content, and in the case of the verification services, what they were able to establish about a supplier. None of them measures anything about a person.

A certificate stating 98.7 per cent purity for a batch supplied by WWB, SSA or KP is silent on that customer’s body composition, and a low-purity result does not explain a disappointing DXA scan. The two questions are answered by different instruments in different buildings, and conflating them produces a particular kind of dead end in which somebody spends several hundred pounds on analytical testing to investigate a clinical question.

The reverse confusion also occurs: a satisfactory laboratory panel or a favourable body-composition scan is offered as evidence that a vial contained what its label claimed. It is not evidence of that either. Compounds sold for research use only are not approved for human use, and nothing in this section should be read as advice about using them.

Protein recommendations in general circulation come largely from athletic populations in energy balance. Naming the source population every time is the simplest corrective available, and it changes how several familiar figures read.

Two things follow practically and only two. Eating adequate protein and loading the skeleton during rapid weight loss are supported by general physiology, carry negligible risk, and are worth doing. Expecting either to prevent lean-mass loss outright is not supported by anything, and treating a fall in a DXA number as a failure of adherence is a misreading of what the number can tell you.